



S/N 10/601,081

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Alan R. Fritzberg et al. Examiner: Unknown  
Serial No.: 10/601,081 Group Art Unit: 1616  
Filed: June 20, 2003 Docket: 295.054US1  
Title: SKELETAL-TARGETED RADIATION TO TREAT BONE-ASSOCIATED PATHOLOGIES

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In compliance with 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to MPEP 609, Applicants request that a copy of the Form 1449, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. § 1.97(b), no fee or statement is required with the Supplemental Information Disclosure Statement. However, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 19-0743 in order to have this Supplemental Information Disclosure Statement considered. The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,  
ALAN R. FRITZBERG ET AL.  
By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.  
P.O. Box 2938  
Minneapolis, MN 55402  
(612) 373-6903

Date 11-18-03

By W.D.C.  
Warren D. Woessner  
Reg. No. 30,440

**CERTIFICATE UNDER 37 CFR 1.8:** The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 18<sup>th</sup> day of November, 2003.

Name

Dawn M. Ponle

Signature

Dawn M. Ponle

NOV 21 2003  
EXAMINER & TRADEMARKS

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>		<i>Complete if Known.</i>				
		<b>Applicant Number</b>	10/601,081			
		<b>Filing Date</b>	June 20, 2003			
		<b>First Named Inventor</b>	Fritzberg, Alan			
		<b>Group Art Unit</b>	1616			
		<b>Examiner Name</b>	Unknown			
Sheet 1 of 1		Attorney Docket No: 295.054US1				

US PATENT DOCUMENTS						
Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
	3,974,268	08/10/1976	Subramanian et al.	424	1	05/30/1975
	5,089,249	02/18/1992	Fritzberg et al.	424	1.1	06/16/1988
	5,202,109	04/13/1993	Fritzberg et al.	424	1.1	01/31/1991

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Foreign Document No	Publication Date				
	EP 0 455 380	11/06/1991				
	WO 01/91806	12/06/2001				
	WO 02/062398	08/15/2002				
	WO 93/25240	12/23/1993				

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	CLEYNHENS et al., "99mTc-EC-AMDP, a Bone Agent with Rapid Clearance from Soft Tissue", <i>Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine</i> , 5, 605-609 (1999).
	COHEN et al., "Bisphosphonates and Tetracycline: Experimental Models for Their Evaluation in Calcium-Related Disorders", <i>Pharmaceutical Research</i> , 15, 606-613 (1998).
	EISENHUT et al., "The Influence of Substituents in 99mTc-Benzylidenediphosphonate Complexes on their Organ Distribution in Rats", <i>Nuklearmedizin</i> , 23, 119-122 (1984).
	FUJISAKI et al., "Physicochemical Characterization of Bisphosphonic Carboxyfluorescein for Osteotropic Drug Delivery", <i>J Pharm Pharmacol.</i> , 48, 798-800 (1996).
	JARVIS et al., "Characterization of the Bisphosphonate Recognition Site on Hydroxyapatite Using Radioligand Binding Techniques with [ <sup>14</sup> C]Citric Acid", <i>Calcif Tissue Int.</i> , 52, 372-377 (1993).
	LARSEN et al., "Preliminary Evaluation of a New Radiolabelled Bisphosphonate", <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , XLI, 823-830 (1998).

EXAMINER

DATE CONSIDERED